IGF-2–activated IR-A especially enhanced BC cell metabolic flexibility, leading to the acquisition of malignant features consistent with cellular adaptation to a challenging microenvironment characterized by high energy demand (Vella et al., 2019b). This evidence concerns the gene IGF2 and breast cancer.